Paul Edwards Posted March 24, 2016 Share Posted March 24, 2016 The New Prostate Cancer Infolink has an article about the announcement of a new clinical trial of Enzalutamide (brand name Xtandi) in men with metastatic, hormone-sensitive prostate cancer. This trial will be recruiting men In Australia. The New Prostate Cancer Infolink expresses concern about the suitability of this trial for men newly diagnosed with a significant presence of metastatic disease. Click on this link to read the article. Link to comment Share on other sites More sharing options...
This topic is now archived and is closed to further replies.